Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 9/20 | 0.64 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5470119 | 0.78 | CHEK1 (1.00) | CHEK1 | |
| SCHEMBL5465647 | 0.77 | CHEK1 (0.64) | CHEK1ADORA2APGRBACE1KCNH2 | |
| SCHEMBL5469935 | 0.76 | CHEK1 (0.54) | CHEK1 | |
| SCHEMBL5473192 | 0.76 | CHEK1 (0.56) | CHEK1ADORA2AADORA1KCNH2 | |
| SCHEMBL5475307 | 0.76 | ADORA1 (0.45) | CHEK1ADORA1 | |
| SCHEMBL5470133 | 0.75 | CHEK1 (0.57) | CHEK1PDPK1ADORA1 | |
| SCHEMBL4500850 | 0.71 | CHEK1 (0.48) | CHEK1ADORA2APGRPIM1ADORA2B | |
| SCHEMBL5478028 | 0.71 | CHEK1 (0.76) | CHEK1 | |
| SCHEMBL5483135 | 0.70 | CHEK1 (1.00) | CHEK1 | |
| SCHEMBL5470234 | 0.70 | CHEK1 (1.00) | CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | US | claimed |
| JP-2006520397-A | — | — | 2006-09-07 | — | — | JP | claimed |
| EP-1613625-A1 | NOVEL FUSED TRIAZOLONES AND THE USES THEREOF | AstraZeneca AB (SE) | 2006-01-11 | — | — | EP | claimed |
| WO-2004081008-A1 | NOVEL FUSED TRIAZOLONES AND THE USES THEREOF | ASTRAZENECA AB (SE) | 2004-09-23 | — | — | WO | claimed |
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | TP53, BRCA1, KLK3 | CHEK1 13/4885ADORA2A 2916/4885PGR 1499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.